lonnie moulder

Lonnie Moulder, M.B.A.

Director

Lonnie is Founder and Managing Member of Tellus BioVentures, an early-stage life sciences investment fund. Prior to establishing Tellus BioVentures he cofounded TESARO and served as CEO and Director until its acquisition by GlaxoSmithKline in January 2019. Lonnie previously served as President and CEO of Abraxis BioScience, acquired by Celgene Corporation in 2010. Prior to Abraxis he served as Vice Chairman of Eisai Corporation of North America following Eisai’s acquisition of MGI PHARMA, where he served as President and CEO. This followed him serving as a member of the founding management team of a venture-stage biotech company. Lonnie began his career as a clinical pharmacist followed by a 17-year career at predecessor companies of Sanofi, beginning with Marion Laboratories.

Lonnie is a Temple University Trustee and serves on the Board of the Fox Chase Cancer Center. He is a Council Member for both the University of Chicago Booth School of Business and the Polsky Center for Entrepreneurship and Innovation. Lonnie serves as the Executive Chair of Zenas BioPharma and on the Board of Directors for Zai Lab, Helsinn Group and Trevena and for the Tellus Bioentures portfolio companies: Aegle Therapeutics, Dianthus Therapeutics, Interius BioTherapeutics, Navrogen and TamuroBio. He received a Pharmacy degree from Temple University and an MBA from The University of Chicago Booth School of Business.

lonnie moulder

Lonnie Moulder, M.B.A.

Director

Lonnie is Founder and Managing Member of Tellus BioVentures, an early-stage life sciences investment fund. Prior to establishing Tellus BioVentures he cofounded TESARO and served as CEO and Director until its acquisition by GlaxoSmithKline in January 2019. Lonnie previously served as President and CEO of Abraxis BioScience, acquired by Celgene Corporation in 2010. Prior to Abraxis he served as Vice Chairman of Eisai Corporation of North America following Eisai’s acquisition of MGI PHARMA, where he served as President and CEO. This followed him serving as a member of the founding management team of a venture-stage biotech company. Lonnie began his career as a clinical pharmacist followed by a 17-year career at predecessor companies of Sanofi, beginning with Marion Laboratories.

Lonnie is a Temple University Trustee and serves on the Board of the Fox Chase Cancer Center. He is a Council Member for both the University of Chicago Booth School of Business and the Polsky Center for Entrepreneurship and Innovation. Lonnie serves as the Executive Chair of Zenas BioPharma and on the Board of Directors for Zai Lab, Helsinn Group and Trevena and for the Tellus Bioentures portfolio companies: Aegle Therapeutics, Dianthus Therapeutics, Interius BioTherapeutics, Navrogen and TamuroBio. He received a Pharmacy degree from Temple University and an MBA from The University of Chicago Booth School of Business.